...
首页> 外文期刊>ACS applied materials & interfaces >Nitric Oxide-Delivering High-Density Lipoprotein-like Nanoparticles as a Biomimetic Nanotherapy for Vascular Diseases
【24h】

Nitric Oxide-Delivering High-Density Lipoprotein-like Nanoparticles as a Biomimetic Nanotherapy for Vascular Diseases

机译:作为血管疾病的血管疾病的一氧化氮递送高密度脂蛋白样纳米颗粒

获取原文
获取原文并翻译 | 示例
           

摘要

Disorders of blood vessels cause a range of severe health problems. As a powerful vasodilator and cellular second messenger, nitric oxide (NO) is known to have beneficial vascular functions. However, NO typically has a short half-life and is not specifically targeted. On the other hand, high-density lipoproteins (HDLs) are targeted natural nanoparticles (NPs) that transport cholesterol in the systemic circulation and whose protective effects in vascular homeo-stasis overlap with those of NO. Evolving the AuNP-templated HDL-like nanoparticles (HDL NPs), a platform of bioinspired HDL, we set up a targeted biomimetic nanotherapy for vascular disease that combines the functions of NO and HDL. A synthetic S-nitrosylated (SNO) phospholipid (1,2-dipalmitoyl-sn-glycero-3-phosphonitrosothioethanol) was synthesized and assembled with S-containing phospholipids and the principal protein of HDL, apolipoprotein A-I, to construct NO-delivering HDL-like particles (SNO HDL NPs). SNO HDL NPs self-assemble under mild conditions similar to natural processes, avoiding the complex postassembly modification needed for most synthetic NO-release nanoparticles. In vitro data demonstrate that the SNO HDL NPs merge the functional properties of NO and HDL into a targeted nanocarrier. Also, SNO HDL NPs were demonstrated to reduce ischemia/reperfusion injury in vivo in a mouse kidney transplant model and atherosclerotic plaque burden in a mouse model of atherosclerosis. Thus, the synthesis of SNO HDL NPs provides not only a bioinspired nanotherapy for vascular disease but also a foundation to construct diversified multifunctional platforms based on HDL NPs in the future.
机译:血管障碍导致一系列严重的健康问题。作为一种强大的血管扩张器和蜂窝蜂窝散发器,已知一氧化氮(NO)具有有益的血管功能。然而,通常没有一个短的半衰期并且没有特别靶向。另一方面,高密度脂蛋白(HDL)是靶向天然纳米颗粒(NPS),其在全身循环中运输胆固醇,其在血管家庭 - Stasis中的保护作用与NO的血管重叠。进化AUNP模板的HDL样纳米颗粒(HDL NPS),Bioinspired HDL的平台,我们为血管疾病建立了靶向染色纳米疗法,这些血管疾病结合了NO和HDL的功能。合成的S-亚硝基吡咯烷化(SnO)磷脂(1,2-Dipalmitoyl-Sn-甘油-3-磷腈噻吩硫醇)合成并组装含S的磷脂和HDL,载脂蛋白AI的主要蛋白,以构建无产HDL-像颗粒(SNO HDL NPS)。 SNO HDL NPS在温和条件下自组装类似于天然过程,避免大多数合成无释放纳米颗粒所需的复杂的锻造改性。体外数据表明,SnO HDL NP将NO和HDL的功能性合并到目标纳米载体中。此外,SnO HDL NPS被证明是为了减少小鼠肾移植模型和动脉粥样硬化小鼠模型中的小鼠肾移植模型和动脉粥样硬化斑块负担的体内缺血/再灌注损伤。因此,SnO HDL NPS的合成不仅提供了用于血管疾病的生物悬浮纳米疗法,而且提供基于未来HDL NPS构建多元化多功能平台的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号